Accustem Sciences (ACUT) Other Non-Current Liabilities (2022 - 2026)
Accustem Sciences (ACUT) posted quarterly Other Non-Current Liabilities of $66000.0 for Q1 2026, down 61.36% year-over-year from $170816.0 in Q1 2025, and down 66.74% quarter-over-quarter from $198424.0 in Q4 2025.
Accustem Sciences (ACUT) Other Non-Current Liabilities (2022 - 2026) Analysis & Trends
Accustem Sciences (ACUT) has reported Other Non-Current Liabilities for 5 consecutive years, with $66000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non-Current Liabilities fell 61.36% year-over-year to $66000.0; the TTM figure through Mar 2026 stood at $66000.0 (down 61.36% YoY), while the FY2025 annual figure was $198424.0, up 149.77% from the prior year.
- Other Non-Current Liabilities declined to $66000.0 in Q1 2026 per ACUT's latest filing, from $198424.0 in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $1.7 million in Q1 2024 and bottomed at $16500.0 in Q2 2025.
- Historically, Other Non-Current Liabilities has averaged $286715.2 across 5 years, with a median of $115500.0 in 2023.
- Annual changes were most pronounced in 2024 — Other Non-Current Liabilities soared 1948.0% — and 2025, when it tumbled 90.0%.
- Accustem Sciences' Other Non-Current Liabilities stood at $66000.0 in 2022, then surged by 100.0% to $132000.0 in 2023, then slumped by 39.82% to $79442.0 in 2024, then jumped by 149.77% to $198424.0 in 2025, then slumped by 66.74% to $66000.0 in 2026.
- Business Quant data shows ACUT's Other Non-Current Liabilities at $66000.0 in Q1 2026, $198424.0 in Q4 2025, and $88296.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Accustem Sciences | 2.57 Mn | 2.56 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 66,000.00 |
| Dec 31, 2025 | 198,424.00 |
| Sep 30, 2025 | 88,296.00 |
| Jun 30, 2025 | 16,500.00 |
| Mar 31, 2025 | 170,816.00 |
| Dec 31, 2024 | 79,442.00 |
| Sep 30, 2024 | 181,500.00 |
| Jun 30, 2024 | 165,000.00 |
| Mar 31, 2024 | 1.65 Mn |
| Dec 31, 2023 | 132,000.00 |
| Sep 30, 2023 | 1.02 Mn |
| Jun 30, 2023 | 99,000.00 |
| Mar 31, 2023 | 80,733.00 |
| Dec 31, 2022 | 66,000.00 |